Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The marine natural products manoalide and scalaradial are potent anti-inflammatory agents that inactivate the enzyme
phospholipase A2
(
PLA2
) in vitro. To study the mechanism of inhibition of prostaglandin E2 (PGE2) production in human monocytes by manoalide and scalaradial,
lipopolysaccharide
(
LPS
)-induced prostaglandin biosynthesis and induction of prostaglandin H synthase (PGHS) were evaluated.
LPS
(10 ng/mL) and interleukin-1 beta (IL-1 beta, 50-1000 ng/mL) but not tumor necrosis factor alpha (TNF alpha, 300 ng/mL) induced the expression of the PGHS-2 isoform as determined by immunoblot analysis with a specific polyclonal antibody for PGHS-2. Manoalide and scalaradial (1-10 microM) inhibited
LPS
-induced endogeneous PGE2 production, reduced the
LPS
-induced PGHS activity, and reduced the expression of PGHS-2. Indomethacin [a PGHS inhibitor (0.01 to 0.1 microM)], zileuton [a 5-lipoxygenase inhibitor (3-10 microM)], and WEB-2806 [a platelet-activating factor (PAF) antagonist (30 microM)] did not affect the
LPS
-induced expression of PGHS-2 in human monocytes. These results suggest that modulation of lipid mediator production by manoalide or scalaradial may not be involved in the observed effects on the expression of PGHS-2. Manoalide and scalaradial also inhibited the release of IL-1 beta and TNF alpha from
LPS
-stimulated monocytes. Expression of PGHS-2 induced by either
LPS
or IL-1 beta was blocked by the IL-1 receptor antagonist (IL-1ra, 2 micrograms/mL) but not by rolipram, a phosphodiesterase IV inhibitor that inhibits TNF alpha but not IL-1 beta release. Similar to
LPS
, IL-1 beta-induced PGHS-2 expression was apparently not regulated by lipid mediators such as prostaglandins, leukotrienes or PAF as determined with specific inhibitors and antagonists. Scalaradial and to some extent manoalide were capable of blocking the IL-1 beta-induced expression of PHGS-2. These results indicate that IL-1 beta is the predominant cytokine responsible for the induction of PGHS-2 in the human monocyte. Furthermore, marine natural products such as scalaradial have novel effects on the IL-1 beta-mediated induction of PGHS-2 in human monocytes, which appears to be independent of effects on lipid mediator production.
...
PMID:Regulation of prostaglandin H synthase 2 expression in human monocytes by the marine natural products manoalide and scalaradial. Novel effects independent of inhibition of lipid mediator production. 757 73
We have shown previously that guinea pig alveolar macrophages (AM) synthesize a secretory
phospholipase A2
(
PLA2
) during in vitro incubation. Here, we report the molecular cloning of this enzyme and show that it has structural features closely related to all known mammalian type-II
PLA2
. The mRNA and
PLA2
activity were undetectable in freshly collected AM, but their levels increased dramatically to reach maximal values after 16 h of culture. Thereafter, the
PLA2
activity remained constant with a parallel secretion in the medium, in contrast to mRNA level which returned to near basal values after 32 h. Incubation of AM for 16 h with the inflammatory secretagogue peptide f-Met-Leu-Phe (fMLP) markedly reduced the
PLA2
activity and mRNA levels. This inhibition was prevented by preexposure of AM to pertussis toxin, an inhibitor of G-protein. In contrast, when AM were first cultured for 16 h and then incubated with fMLP, no significant change was observed in their
PLA2
activity. In conditions where the type-II
PLA2
was completely abrogated by fMLP, the latter did not alter the
lipopolysaccharide
-induced accumulation of tumor necrosis factor alpha mRNA or the release of arachidonic acid induced by the subsequent addition of the calcium ionophore A23187. These studies show that the inflammatory peptide fMLP down-regulates the expression of the type-II
PLA2
by AM through a process mediated by G-protein. A possible negative control of the type-II
PLA2
expression during AM activation is suggested.
...
PMID:Expression of the type-II phospholipase A2 in alveolar macrophages. Down-regulation by an inflammatory signal. 761 34
Ninety minutes after i.v. injection of Escherichia coli
lipopolysaccharide
(
LPS
) (1 mg/kg) into rats, phorbol 12-myristate 13-acetate (PMA)-stimulated superoxide anion (O2-) secretion was enhanced in suspensions of in vivo
LPS
-treated alveolar macrophages (AM phi) when compared with saline (SAL)-treated AM phi. The purpose of this investigation was to dissect the in vitro mechanism of PMA-stimulated O2- generation in both
LPS
and SAL-treated rat AM phi, with a panel of inhibitors of protein kinase C (PKC), protein serine-threonine phosphatase(s) (PSP), protein tyrosine kinase(s) (PTK) and phosphatase(s) (PTP),
phospholipase A2
(
PLA2
), cyclooxygenase (CO) and 5-lipoxygenase (5-LO). The following agents blocked PMA-stimulated O2- generation in both
LPS
- and SAL-treated AM phi (expressed as percentage of control): 1) PKC inhibitors: staurosporine: 100 nM, 7.0% (
LPS
) and 5.6% (SAL); sphingosine: 10 microM, 21% (
LPS
) and 10.5% (SAL); 2) PTK inhibitor: genistein: 100 microM, 44% (
LPS
) and 31% (SAL); 3) PTP inhibitors: phenylarsine oxide, 10 microM, 12.1% (
LPS
) and 18% (SAL); diamide, 1000 microM, 10.1% (
LPS
) and 10.5% (SAL); and 4)
PLA2
inhibitors: manoalide: 1 microM, 29.3% (
LPS
) and 5.2% (SAL); scalaradial: 1 microM, 7.7% (
LPS
) and 7.1% (SAL); and WAY 125,984: 10 microM, 17.1% (
LPS
) and 14.5% (SAL). In addition, it was observed that exogenously added arachidonic acid (AA)-stimulated O2- generation in a time- and dose-dependent manner in both
LPS
and SAL-treated AM phi. The following inhibitors enhanced or did not affect PMA-stimulated O2- generation in
LPS
- and SAL-treated AM phi (expressed as percentage of of control): 1) PSP inhibitors: okadaic acid: 0.5 microM, 117% (
LPS
) and 153% (SAL); calyculin A: 1 microM, 112% (
LPS
) and 101% (SAL); 2) CO and 5-LO inhibitors: indomethacin: 10 microM, 107% (
LPS
) and 90% (SAL); WY 50, 295: 1 microM, 99% (
LPS
) and 103% (SAL); and 3) the PTP inhibitor orthovanadate upon prolonged preincubation. In both in vivo
LPS
- or SAL-primed AM phi, PMA-stimulated O2- generation appears to be modulated by PKC,
PLA2
, AA, PTK, PTP and PSP. No modulatory role was evident for either CO or 5-LO metabolites. These findings might bear on the design of therapeutic approaches for the modulation of O2- release by AM phi in the early stages of sepsis and adult respiratory distress syndrome.
...
PMID:Modulation of superoxide generation in in vivo lipopolysaccharide-primed rat alveolar macrophages by arachidonic acid and inhibitors of protein kinase C, phospholipase A2, protein serine-threonine phosphatase(s), protein tyrosine kinase(s) and phosphatase(s). 761 27
We examined whether inhibitors of the arachidonic acid cascade inhibited nitric oxide (NO) production, as measured by nitrite concentration, either in macrophages or by their cytosolic fractions. Nitrite production by peritoneal macrophages from mice receiving OK-432 treatment was significantly inhibited by
phospholipase A2
inhibitors [dexamethasone and 4-bromophenacyl bromide (4-BPB)], lipoxygenase inhibitors [nordihydroguaiaretic acid (NDGA) and ketoconazole] and a glutathione S-transferase (leukotrienes LTA4-LTC4) inhibitor (ethacrynic acid). However, caffeic acid and esculetin, inhibitors of 5- and 12-lipoxygenase respectively, were not inhibitory. On the other hand, indomethacin, a cyclooxygenase inhibitor, slightly inhibited whereas another inhibitor, ibuprofen, did not. Inhibition of the nitrite production by dexamethasone, 4-BPB, NDGA and ethacrynic acid was also demonstrated when the macrophages were restimulated ex vivo with OK-432 or with
lipopolysaccharide
. The inhibitory activity of dexamethasone, NDGA and ethacrynic acid was significantly reduced by ex vivo restimulation with OK-432, whereas that of 4-BPB was hardly affected. Furthermore, the inhibitory activity of dexamethasone, NDGA and ethacrynic acid was much higher when the macrophages were continuously exposed to the agents than when they were pulsed. Meanwhile, inhibition by 4-BPB was almost the same with either treatment. In addition, the inhibitory activity of these agents was not blocked with L-arginine, a substrate of NO synthases, or with arachidonate metabolites (LTB4, LTC4 and LTE4). Ethacrynic acid and 4-BPB, but not dexamethasone and NDGA, also inhibited nitrite production by the cytosolic fractions from OK-432-restimulated peritoneal macrophages, and the inhibitory activity of 4-BPB was superior to that of ethacrynic acid. These agents, however, did not inhibit nitrite production from sodium nitroprusside, a spontaneous NO-releasing compound. These results indicate that dexamethasone, 4-BPB, NDGA and ethacrynic acid inhibited the production of NO by macrophages through at least two different mechanisms: one was inhibited by dexamethasone, NDGA and ethacrynic acid and the other by 4-BPB. Furthermore, 4-BPB and ethacrynic acid directly inhibited the activity of the NO synthase in macrophages, suggesting that the agents work by binding to the active site(s) of the enzyme.
...
PMID:Inhibition of macrophage nitric oxide production by arachidonate-cascade inhibitors. 769 96
CGP 47969A is a novel piperazine derivative that inhibits the synthesis of inflammatory cytokines, such as interleukin-1 alpha (IL-1), IL-1 beta and tumor necrosis factor alpha (TNF), in human monocytes stimulated with
lipopolysaccharide
(
LPS
), zymosan or IL-1 itself. IC50 values are in the range of 0.3-5 mumol/l. CGP 47969A does not inhibit total protein or RNA synthesis indicating selectivity for cytokine inhibition. CGP 47969A exerts its inhibitory effect at a post-transcriptional level, most probably by reducing translational efficiency of IL-beta mRNA, as steady-state levels of IL-1 beta mRNA are not inhibited while the primary translation product, the 31 kD IL-1 beta precursor molecule, is dose-dependently inhibited by CGP 47969A. The compound is devoid of cyclooxygenase and
phospholipase A2
inhibitory activity but efficiently inhibits the generation of PGE2 and LTC4 in zymosan-stimulated mouse macrophages with an IC50 of 1.2 and 0.6 mumol/l, respectively. Antagonism of IL-1 and/or TNF is thought to have a beneficial effect on the course of inflammatory diseases. CGP 47969A may therefore represent a mechanistically new approach to the treatment of such diseases.
...
PMID:CGP 47969A: a novel inhibitor of the synthesis of inflammatory cytokines. 774 Oct 42
Interleukin-1 (IL-1) and IL-6 are produced by Sertoli cells. As IL-1 stimulates IL-6 production in some tissues, the cascade of events that results in IL-6 secretion by Sertoli cells was studied. The addition of IL-1 alpha to Sertoli cells resulted in a time-dependent increase in IL-6 secretion. Incubation of Sertoli cells with two known stimulators of IL-1 production,
lipopolysaccharide
(
LPS
) and residual bodies, resulted in a significant increase in IL-1 release into the medium several hours before IL-6 release. That IL-1 is essential for IL-6 production from Sertoli cells was established by blocking the actions of
LPS
and residual bodies with an anti-IL-1 alpha antibody. An increase in the release of IL-1 before IL-6 was also observed in medium obtained from staged segments of intact seminiferous tubules; IL-1 reached a maximum level at stage VIII, when mature spermatozoa are released and residual bodies are formed and phagocytosed. The secretion of IL-6 was low during this stage and then increased progressively from stage IX onward, consistent with IL-1 stimulation of IL-6. The pathway of IL-1 alpha-induced release of IL-6 was studied in the presence of agents that influence arachidonic acid release and metabolism. IL-1 alpha was found to stimulate arachidonic acid release by Sertoli cells. Furthermore, a
phospholipase A2
inhibitor, aristolochic acid, significantly decreased IL-1-,
LPS
-, and pyrularia pubera thionin-induced IL-6 secretion from Sertoli cells. Indomethacin, a specific inhibitor of the cyclooxygenase pathway, had no significant effect on basal, but enhanced IL-1- and
LPS
-stimulated IL-6 production. The involvement of arachidonic acid metabolites produced in the lipoxygenase pathway on the release of IL-6 was investigated indirectly, using nordihydroguaiaretic acid. This inhibitor reduced basal and IL-1 alpha- and
LPS
-stimulated IL-6 production. Ethacrynic acid, an inhibitor of peptido-leukotriene synthesis, also reduced basal IL-6 levels and blocked IL-1 alpha- as well as
LPS
-induced IL-6 secretion. It is concluded that IL-1 produced by Sertoli cells in response to
LPS
or residual bodies induces IL-6 through the lipoxygenase pathway.
...
PMID:Residual bodies activate Sertoli cell interleukin-1 alpha (IL-1 alpha) release, which triggers IL-6 production by an autocrine mechanism, through the lipoxygenase pathway. 778 34
Circulating proinflammatory mediators have not been found in studies on typhoid fever, although the patients suffer from a systemic disease with characteristic protracted fever. The 14-kDa group II extracellular
phospholipase A2
(
PLA2
) is induced by interleukin-1 and tumor necrosis factor and may mediate some of the effects of these cytokines. Circulating
PLA2
concentrations were measured in 12 typhoid fever patients on various days after admission and after recovery. On admission, mean concentrations of
PLA2
were elevated (1444 +/- 1560 ng/mL) and decreased gradually and significantly to day 14 (55 +/- 48 ng/mL). patients with complicated disease had significantly higher
PLA2
levels on admission.
PLA2
was not produced in a
lipopolysaccharide
-stimulated whole blood culture, indicating that
PLA2
originates from other types of cells. These data indicate that
PLA2
may be a mediator of disease in protracted inflammatory diseases such as thyroid fever.
...
PMID:Phospholipase A2 is a circulating mediator in typhoid fever. 779 37
Studies were conducted to characterize a human monocyte model where the role of the 85-kDa
phospholipase A2
(
PLA2
) in prostanoid formation could be evaluated. The presence of an immunologically related 85-kDa
PLA2
and type II 14-kDa
PLA2
was demonstrated in human monocytes and their roles examined in
lipopolysaccharide
(
LPS
)-induced monocyte prostaglandin E2 (PGE2) formation. Exposure of human monocytes to
LPS
over 18 h resulted in the up-regulation of the mitogen-inducible cyclooxygenase-2 and was accompanied by production and release of prostaglandin E2 but not leukotriene C4. This coincided with a 2-fold increase in the 85-kDa
PLA2
protein and activity levels. In contrast, there was no effect on the type II 14-kDa-like
PLA2
activity measured in the 100,000 x g particulate fraction nor did
LPS
induce the release of type II 14-kDa
PLA2
into the medium. Treatment with cycloheximide over 18 h resulted in a time-dependent decrease in cytosolic 85-kDa
PLA2
protein and activity (half-life = 4 h), but there was no change in the particulate type II 14-kDa-like
PLA2
activity. Monocytes were therefore exposed to an 85-kDa
PLA2
initiation site-directed antisense oligonucleotide which specifically decreased the cytosolic 85-kDa
PLA2
protein levels and activity in a concentration-dependent manner. This had no effect on the cyclooxygenase-2 (protein mass or the ability to convert arachidonic acid to PGE2) or the particulate fraction sn-2 acylhydrolytic activity but was associated with a decrease in
LPS
-induced PGE2 production. Taken together, these data support a role for the cytosolic 85-kDa
PLA2
in
LPS
-induced monocyte PGE2 formation.
...
PMID:Suppression of monocyte 85-kDa phospholipase A2 by antisense and effects on endotoxin-induced prostaglandin biosynthesis. 792 10
Macrophage-like P388D1 cells mobilize arachidonic acid (AA) and produce prostaglandin E2 upon stimulation with bacterial
lipopolysaccharide
and platelet-activating factor. We have now demonstrated that AA mobilization in these cells is composed of two distinct events: a transient phase in which AA accumulates in the cell and a sustained phase in which the fatty acid accumulates in the incubation medium. Both phases are markedly dependent on the presence of Ca2+ in the extracellular medium. Treatment with an antisense oligonucleotide to group II
phospholipase A2
inhibits the accumulation of AA in the incubation medium, but has no effect on the accumulation of this fatty acid in the cell. In addition, treatment with antisense oligonucleotide to group II
phospholipase A2
has no effect on the uptake or the esterification of AA. Collectively, these results indicate that, in addition to the previously demonstrated role of group II
phospholipase A2
in AA mobilization in activated P388D1 cells, another
phospholipase A2
, distinct from the group II enzyme, is implicated in raising the levels of intracellular AA during the early steps of P388D1 cell activation and in modulating deacylation/reacylation reactions involving AA. The data suggest that each of the different
phospholipase A2
enzymes present in P388D1 cells serves a distinct role in cell function.
...
PMID:Arachidonic acid mobilization in P388D1 macrophages is controlled by two distinct Ca(2+)-dependent phospholipase A2 enzymes. 797 9
Cultures of mouse peritoneal resident macrophages produced prostaglandin E2 when exposed to extracellular group II
phospholipase A2
. The response to group II
phospholipase A2
was concentration dependent, and prostaglandin E2 production in response to 1 microgram/ml purified group II enzyme was comparable to the maximal response elicited by
lipopolysaccharide
. Group II
phospholipase A2
required millimolar concentrations of extracellular Ca2+ for the induction of prostaglandin E2 production, as well as for
phospholipase A2
activity. YM-26734 (4-(3,5-didodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyph eny l) chroman), a selective inhibitor of group II
phospholipase A2
, inhibited not only the enzyme activity but also the prostaglandin E2 production-inducing activity of group II
phospholipase A2
in a concentration-dependent manner. These findings suggest that group II
phospholipase A2
released into the extracellular space may induce prostaglandin E2 production through hydrolysis of plasma membrane phospholipids. Taken together with the previous finding that YM-26734 suppressed inflammatory responses in vivo, these results suggest that group II
phospholipase A2
may play a role in the excitation and/or progression of inflammatory processes through the production of eicosanoids.
...
PMID:Exogenous group II phospholipase A2 induces prostaglandin E2 production in mouse peritoneal macrophages. 801 41
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>